Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
Abstract Background Trastuzumab (T-mab)-based chemotherapy is a standard regimen for human epithelial growth factor 2 (HER2)-positive gastric cancer. However, some patients have demonstrated a change in HER2 status after T-mab-based treatment of breast cancer. We report a rare case of mixed adenoneu...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2020-01-01
|
| Series: | Surgical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40792-020-0774-7 |
| _version_ | 1819330606642757632 |
|---|---|
| author | Hiromi Nagata Hironori Tsujimoto Yoshihisa Yaguchi Keita Kouzu Yujiro Itazaki Yusuke Ishibashi Satoshi Tsuchiya Takao Sugihara Nozomi Ito Manabu Harada Shinsuke Nomura Yoshitaka Utsumi Hideyuki Shimazaki Yoji Kishi Hideki Ueno |
| author_facet | Hiromi Nagata Hironori Tsujimoto Yoshihisa Yaguchi Keita Kouzu Yujiro Itazaki Yusuke Ishibashi Satoshi Tsuchiya Takao Sugihara Nozomi Ito Manabu Harada Shinsuke Nomura Yoshitaka Utsumi Hideyuki Shimazaki Yoji Kishi Hideki Ueno |
| author_sort | Hiromi Nagata |
| collection | DOAJ |
| description | Abstract Background Trastuzumab (T-mab)-based chemotherapy is a standard regimen for human epithelial growth factor 2 (HER2)-positive gastric cancer. However, some patients have demonstrated a change in HER2 status after T-mab-based treatment of breast cancer. We report a rare case of mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after T-mab-based chemotherapy for HER2-positive gastric cancer. Case presentation A 60-year-old man presented with a mass of the upper abdomen, which was diagnosed as adenocarcinoma with a HER2 score of 3+ by endoscopic biopsy. He received seven cycles of combination chemotherapy with capecitabine, cisplatin, and T-mab. Subsequently, he underwent open total gastrectomy, distal pancreatosplenectomy, and extended left hepatic lobectomy as a conversion surgery. The surgically resected specimen demonstrated both adenocarcinoma and neuroendocrine components; therefore, it was diagnosed as HER2-negative mixed adenoneuroendocrine carcinoma. Although the patient received additional chemotherapy, multiple liver metastases appeared at 3 months postoperatively and he died at 6 months postoperatively because of the rapidly progressing metastatic tumor. Conclusions We encountered a rare case of rapidly progressive mixed adenoneuroendocrine carcinoma that was negative for HER2 expression after T-mab treatment combined with chemotherapy. |
| first_indexed | 2024-12-24T14:01:12Z |
| format | Article |
| id | doaj.art-c8d2d582a64a48efbab4f32db8699ac4 |
| institution | Directory Open Access Journal |
| issn | 2198-7793 |
| language | English |
| last_indexed | 2024-12-24T14:01:12Z |
| publishDate | 2020-01-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Surgical Case Reports |
| spelling | doaj.art-c8d2d582a64a48efbab4f32db8699ac42022-12-21T16:52:29ZengSpringerOpenSurgical Case Reports2198-77932020-01-01611610.1186/s40792-020-0774-7Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case reportHiromi Nagata0Hironori Tsujimoto1Yoshihisa Yaguchi2Keita Kouzu3Yujiro Itazaki4Yusuke Ishibashi5Satoshi Tsuchiya6Takao Sugihara7Nozomi Ito8Manabu Harada9Shinsuke Nomura10Yoshitaka Utsumi11Hideyuki Shimazaki12Yoji Kishi13Hideki Ueno14Department of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Pathology, National Defense Medical CollegeDepartment of Pathology, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeDepartment of Surgery, National Defense Medical CollegeAbstract Background Trastuzumab (T-mab)-based chemotherapy is a standard regimen for human epithelial growth factor 2 (HER2)-positive gastric cancer. However, some patients have demonstrated a change in HER2 status after T-mab-based treatment of breast cancer. We report a rare case of mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after T-mab-based chemotherapy for HER2-positive gastric cancer. Case presentation A 60-year-old man presented with a mass of the upper abdomen, which was diagnosed as adenocarcinoma with a HER2 score of 3+ by endoscopic biopsy. He received seven cycles of combination chemotherapy with capecitabine, cisplatin, and T-mab. Subsequently, he underwent open total gastrectomy, distal pancreatosplenectomy, and extended left hepatic lobectomy as a conversion surgery. The surgically resected specimen demonstrated both adenocarcinoma and neuroendocrine components; therefore, it was diagnosed as HER2-negative mixed adenoneuroendocrine carcinoma. Although the patient received additional chemotherapy, multiple liver metastases appeared at 3 months postoperatively and he died at 6 months postoperatively because of the rapidly progressing metastatic tumor. Conclusions We encountered a rare case of rapidly progressive mixed adenoneuroendocrine carcinoma that was negative for HER2 expression after T-mab treatment combined with chemotherapy.https://doi.org/10.1186/s40792-020-0774-7Trastuzumab-based chemotherapyGastric cancerConversion surgeryLiver metastasisPrognosis |
| spellingShingle | Hiromi Nagata Hironori Tsujimoto Yoshihisa Yaguchi Keita Kouzu Yujiro Itazaki Yusuke Ishibashi Satoshi Tsuchiya Takao Sugihara Nozomi Ito Manabu Harada Shinsuke Nomura Yoshitaka Utsumi Hideyuki Shimazaki Yoji Kishi Hideki Ueno Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report Surgical Case Reports Trastuzumab-based chemotherapy Gastric cancer Conversion surgery Liver metastasis Prognosis |
| title | Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report |
| title_full | Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report |
| title_fullStr | Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report |
| title_full_unstemmed | Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report |
| title_short | Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report |
| title_sort | mixed adenoneuroendocrine carcinoma with loss of her2 positivity after trastuzumab based chemotherapy for her2 positive gastric cancer a case report |
| topic | Trastuzumab-based chemotherapy Gastric cancer Conversion surgery Liver metastasis Prognosis |
| url | https://doi.org/10.1186/s40792-020-0774-7 |
| work_keys_str_mv | AT hirominagata mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT hironoritsujimoto mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT yoshihisayaguchi mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT keitakouzu mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT yujiroitazaki mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT yusukeishibashi mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT satoshitsuchiya mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT takaosugihara mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT nozomiito mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT manabuharada mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT shinsukenomura mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT yoshitakautsumi mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT hideyukishimazaki mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT yojikishi mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport AT hidekiueno mixedadenoneuroendocrinecarcinomawithlossofher2positivityaftertrastuzumabbasedchemotherapyforher2positivegastriccanceracasereport |